



(12) Translation of
European patent specification

(11) NO/EP 2948461 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 498/22 (2006.01)
A61K 31/535 (2006.01)
A61P 31/04 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.05.11
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.12.25
(86)	European Application Nr.	14702642.1
(86)	European Filing Date	2014.01.22
(87)	The European Application's Publication Date	2015.12.02
(30)	Priority	2013.01.23, US, 201361755537 P 2013.07.30, US, 201361859910 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Entasis Therapeutics Limited, 3rd Floor 1 Ashley Road, AltrinchamCheshire WA14 2DT, Storbritannia
(72)	Inventor	BASARAB, Gregory, Steven, AstraZeneca R&D Boston35 Gatehouse Drive, Waltham, Massachusetts 02451, USA GOWRAVARAM, Madhusudhan, Reddy, c/o Astrazeneca Intellectual PropertyAstraZeneca R&D Boston35 Gatehouse Drive, Waltham, Massachusetts 02451, USA HAUCK, Sheila, Irene, c/o Astrazeneca Intellectual PropertyAstraZeneca R&D Boston35 Gatehouse Drive, Waltham, Massachusetts 02451, USA ZHOU, Fei, AstraZeneca R&D Boston35 Gatehouse Drive, Waltham, Massachusetts 02451, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge


(54)	Title	COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS
(56)	References Cited:	WO-A1-2004/031195 WO-A1-2010/043893 WO-A2-2006/120563 WO-A1-2007/072151

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

2948461

Patentkrav

1. Forbindelse eller farmasøytisk akseptabelt salt derav, hvori forbindelsen har strukturen i formel (I):



hvori:

X er fluor eller klor;

R¹ velges fra gruppen bestående av hydrogen, fenyl, -C=N, tetrahydropyranyl, N-metyl-1,2,4-triazolyl, pyrimidinyl, pyridinyl, pyrazinyl, syklopropyl, -C=CH, -CH=CH₂ og C₁-C₃ alkyl, hvor C₁-C₃ alkyl eventuelt substitueres med én eller flere av: -OR¹⁰, halogen, -C≡N, -N₃, -SO₂CH₃, -SCH₃, -CH=CH₂, -CH=NOR¹¹ og fenyl;

R² velges fra gruppen bestående av hydrogen, -C=N, pyridinyl, C₁-C₃ alkyl, hvor C₁-C₃ alkyl eventuelt substitueres med én eller flere av: halogen, -OR²⁰ og -CH=NOR²¹;

R³ er hydrogen eller C₁-C₃ alkyl;

R¹⁰ velges i hvert tilfelle uavhengig fra gruppen bestående av hydrogen, C₁-C₄ alkyl og - (CH₂)₂OCH₃; og

R¹¹, R²⁰ og R²¹ er i hvert tilfelle uavhengig hydrogen eller C₁-C₄ alkyl.

2. Forbindelsen eller farmasøytisk akseptabelt salt derav, ifølge krav 1, hvori R¹⁰ er hydrogen,

2948461

metyl, etyl eller $-(CH_2)_2OCH_3$.

3. Forbindelsen eller farmasøytisk akseptabelt salt derav, ifølge krav 1 eller 2, hvori R^{11} er hydrogen eller metyl.

5

4. Forbindelsen eller farmasøytisk akseptabelt salt derav, ifølge hvilket som helst av kravene 1–3, hvori R^{20} er hydrogen, metyl eller etyl.

10

5. Forbindelsen eller farmasøytisk akseptabelt salt derav, ifølge hvilket som helst av kravene 1–4, hvori R^{21} er hydrogen eller metyl.

15

6. Forbindelsen eller farmasøytisk akseptabelt salt derav, ifølge hvilket som helst av kravene 1–5, hvori R^1 velges fra gruppen bestående av hydrogen, metyl, etyl, fenyl, $-CH_2$ -fenyl, $-CH_2F$, $-CH_2OCH_3$, $-CH_2CH=CH_2$, tetrahydropyranyl, $-(CH_2)_3OH$, $-(CH_2)_3F$, $-(CH_2)_3OH$, $-(CH_2)_3F$, $-CH=CH_2$, $-C\equiv N$, $-CH=NOCH_3$, $-CH_2SCH_3$, $-CH_2SO_2CH_3$, $-CH_2N_3$, $-CH_2OCH_2CH_3$, $-CH_2O(CH_2)_2OCH_3$, syklopropyl, pyridinyl, $-CH(CH_3)OCH_3$, pyrimidinyl, pyrazinyl, $-C\equiv CH$, N-metyl-1,2,4-triazolyl, $-CH(OH)CH_3$, $-CH=NOH$ og $-CH_2OH$.

20

7. Forbindelsen eller farmasøytisk akseptabelt salt derav, ifølge hvilket som helst av kravene 1–6, hvori R^2 velges fra gruppen bestående av hydrogen, metyl, etyl, $-CH_2F$, $-CH_2OCH_3$, $-CH_2OH$, $-CH=NOH$, pyridinyl, $-C\equiv N$ og $-CH=NHOCH_3$.

25

8. Forbindelsen eller farmasøytisk akseptabelt salt derav, ifølge hvilket som helst av kravene 1–7, hvori R^3 er hydrogen eller metyl.

9. Forbindelsen eller farmasøytisk akseptable salter derav, ifølge hvilket som helst av kravene 1–8, hvori forbindelsen velges fra gruppen bestående av:

30

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-(2-okso-1,3-oksazolidin-3-yl)-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'-(1'*H*,3'*H*)-trion;

2948461

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-[(4*R*)-4-metyl-2-okso-1,3-oksazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-[(5*S*)-5-metyl-2-okso-1,3-oksazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-[(5*R*)-5-metyl-2-okso-1,3-oksazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-[(4*S*)-4-metyl-2-okso-1,3-oksazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-[(4*S*)-4-etyl-2-okso-1,3-oksazolidin-3-yl]-11-fluor-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-[(4*R*)-4-etyl-2-okso-1,3-oksazolidin-3-yl]-11-fluor-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion);

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-[(4*R*)-2-okso-4-phenyl-1,3-oksazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-[(4*S*)-2-okso-4-phenyl-1,3-oksazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-[(4*R*)-4-Benzyl-2-okso-1,3-oksazolidin-3-yl]-11-fluor-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

2948461

(2*R*,4*S*,4*aS*)-8-[(4*S*)-4-Benzyl-2-okso-1,3-oksazolidin-3-yl]-11-fluor-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'-(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-(5,5-dimetyl-2-okso-1,3-oksazolidin-3-yl)-11-fluor-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'-(1'*H*,3'*H*)-trion; (2*R*,4*S*,4*aS*)-8-[(5*S*)-5-etyl-2-okso-1,3-oksazolidin-3-yl]-11-fluor-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'-(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-[(5*R*)-5-etyl-2-okso-1,3-oksazolidin-3-yl]-11-fluor-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'-(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-[(4*R*)-4-(fluormetyl)-2-okso-1,3-oksazolidin-3-yl]-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'-(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-[(4*S*)-4-(fluormetyl)-2-okso-1,3-oksazolidin-3-yl]-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'-(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-[(4*S*)-4-(metoksymetyl)-2-okso-1,3-oksazolidin-3-yl]-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'-(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-[(4*R*)-4-(metoksymetyl)-2-okso-1,3-oksazolidin-3-yl]-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'-(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-[(*S*)-5-(fluormetyl)-2-oksooksazolidin-3-yl]-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'-(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-klor-8-[(5*S*)-4-(metoksymetyl)-2-okso-1,3-oksazolidin-3-yl]-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'-(1'*H*,3'*H*)-trion;

2948461

(2*R*,4*S*,4*aS*)-11 -klor-8-[(5*R*)-4-(metoksymetyl)-2-okso-1,3-oksazolidin-3-yl]-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

((2*R*,4*S*,4*aS*)-11-klor-2,4-dimetyl-8-((*R*)-5-metyl-2-oksooksazolidin-3-yl)-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-((4*S*,5*R*)-4,5-dimetyl-2-oksooksazolidin-3-yl)-11-fluor-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-((4*R*,5*S*)-4,5-dimetyl-2-oksooksazolidin-3-yl)-11-fluor-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-((*S*)-4-allyl-2-oksooksazolidin-3-yl)-11-fluor-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-((*S*)-5-(hydroksymetyl)-2-oksooksazolidin-3-yl)-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

((2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-[(4*R*)-(tetrahydro-2*H*-pyran-4-yl)-2-okso-1,3-oksazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-[(4*S*)-(tetrahydro-2*H*-pyran-4-yl) -2-okso-1,3-oksazolidin-3-yl]-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion; (2*R*,4*S*,4*aS*)-11-

fluor-8-((*S*)-4-(3-hidroksypropyl)-2-oksooksazolidin-3-yl)-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

2948461

(2*R*,4*S*,4*aS*)-11-fluor-8-((*S*)-4-(3-fluorpropyl)-2-oksooksazolidin-3-yl)-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-((*S*)-4-(2-hidroksyetyl)-2-oksooksazolidin-3-yl)-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-klor-8-((*S*)-5-(fluormetyl)-2-oksooksazolidin-3-yl)-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-chor-8-((*S*)-4-(3-hidrokspropyl)-2-oksooksazolidin-3-yl)-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-chor-8-((*S*)-4-(3-fluorpropyl)-2-oksooksazolidin-3-yl)-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-[(5*S*)-4-(metoksymetyl)-2-okso-1,3-oksazolidin-3-yl]-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-[(5*R*)-4-(metoksymetyl)-2-okso-1,3-oksazolidin-3-yl]-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-[(5*R*)-5-(hidroksymetyl)-2-okso-1,3-oksazolidin-3-yl]-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-[(5*R*)-5-(fluormetyl)-2-okso-1,3-oksazolidin-3-yl]-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

2948461

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-((*S*)-2-okso-4-vinyloksazolidin-3-yl)-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-((5*R*)-5-[(hydroksyimino)metyl]-2-okso-1,3-oksazolidin-3-yl)-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(4*S*)-3-[(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-2',4',6'-triokso-1,1',2,3',4,4',4*a*,6'-oktahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-8-yl)-2-okso-1,3-oksazolidin-4-karbonitril;

(2*R*,4*S*,4*aS*)-11-fluor-8-((4*S*)-4-[(metoksyimino)metyl]-2-okso-1,3-oksazolidin-3-yl)-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-((5*R*)-5-(metoksyimino)metyl)-2-okso-1,3-oksazolidin-3-yl)-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-((*R*)-4-((metyltio)metyl)-2-oksooksazolidin-3-yl)-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-((*R*)-4-((metylsulfonyl)metyl)-2-oksooksazolidin-3-yl)-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-((*R*)-4-(azidometyl)-2-oksooksazolidin-3-yl)-11-fluor-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-((*S*)-4-(azidometyl)-2-oksooksazolidin-3-yl)-11-fluor-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

2948461

(2*R*,4*S*,4*aS*)-8-[(4*S*)-4-(etoksymetyl)-2-okso-1,3-oksazolidin-3-yl]-11-fluor-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'-(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-[(4*S*)-4-[(2-metoksyetoksy)metyl]-2-okso-1,3-oksazolidin-3-yl]-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'-(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-[(*R*)-4-(difluormetyl)-2-oksooksazolidin-3-yl]-11-fluor-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'-(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-[(*S*)-4-syklopropyl-2-oksooksazolidin-3-yl]-11-fluor-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'-(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-[(*R*)-2-okso-5-(pyridin-2-yl)oksazolidin-3-yl]-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'-(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-[(*S*)-2-okso-5-(pyridin-2-yl)oksazolidin-3-yl]-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'-(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-[(*R*)-2-okso-4-(pyridin-2-yl)oksazolidin-3-yl]-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'-(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-[(*S*)-2-okso-4-(pyridin-2-yl)oksazolidin-3-yl]-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'-(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-[(*R*)-2-okso-4-(pyridin-4-yl)oksazolidin-3-yl]-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'-(3'*H*)-trion;

2948461

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-((*S*)-2-okso-4-(pyridin-4-yl)oksazolidin-3-yl)-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-((*R*)-4-((*R*)-1-metoksyetyl)-2-oksooksazolidin-3-yl)-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-8-((*R*)-4-((*S*)-1-metoksyetyl)-2-oksooksazolidin-3-yl)-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-((*R*)-2-okso-4-(pyrazin-2-yl)oksazolidin-3-yl)-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-((*S*)-2-okso-4-(pyrazin-2-yl)oksazolidin-3-yl)-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-((*R*)-2-okso-4-(pyrimidin-2-yl)oksazolidin-3-yl)-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-((*S*)-2-okso-4-(pyrimidin-2-yl)oksazolidin-3-yl)-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-((*S*)-4-etynyl-2-oksooksazolidin-3-yl)-11-fluor-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-klor-2,4-dimetyl-8-((*S*)-4-metyl-2-oksooksazolidin-3-yl)-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

2948461

(2*R*,4*S*,4*aS*)-11-fluor-8-[(4*S*)-4-(metoksymetyl)-2-okso-1,3-oksazolidin-3-yl]-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-((*S*)-4-(1-metyl-1*H*-1,2,4-triazol-5-yl)-2-oksooksazolidin-3-yl)-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-8-((*R*)-4-(1-metyl-1*H*-1,2,4-triazol-5-yl)-2-oksooksazolidin-3-yl)-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion; (2*R*,4*S*,4*aS*)-11-fluor-8-((*R*)-4-((*S*)-1-hidroksyetyl)-2-oksooksazolidin-3-yl)-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

{(4*S*)-3-[(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-2',4',6'-triokso-1,1',2,3',4,4',4*a*,6'-oktahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-8-yl]-2-okso-1,3-oksazolidin-4-yl}acetonitril;

(2*R*,4*S*,4*aS*)-8-((*R*)-4-((*R*)-1,2-dihidroksyetyl)-2-oksooksazolidin-3-yl)-11-fluor-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;

(2*R*,4*S*,4*aS*)-8-((*R*)-4-((*S*)-1,2-dihidroksyetyl)-2-oksooksazolidin-3-yl)-11-fluor-2,4-dimetyl-2,4,4*a*,6-tetrahydro-1*H*,1'*H*-spiro[isoksazolo[4,5-*g*][1,4]oksazino[4,3-*a*]quinolin-5,5'-pyrimidin]-2',4',6'(3'*H*)-trion;


(2*R*,4*S*,4*aS*)-11-fluor-8-[(4*S*)-4-[(hidroksyimino)metyl]-2-okso-1,3-oksazolidin-3-yl]-2,4-dimetyl-1,2,4,4*a*-tetrahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-2',4',6'(1'*H*,3'*H*)-trion;

(5*R*)-3-[(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-2',4',6'-triokso-1,1',2,3',4,4',4*a*,6'-oktahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-8-yl]-2-okso-1,3-oksazolidin-5-karbonitril; og

2948461

(5S)-3-[(2*R*,4*S*,4*aS*)-11-fluor-2,4-dimetyl-2',4',6'-triokso-1,1',2,3',4,4',4*a*,6'-oktahydro-2'*H*,6*H*-spiro[1,4-oksazino[4,3-*a*][1,2]oksazolo[4,5-*g*]quinolin-5,5'-pyrimidin]-8-yl]-2-okso-1,3-oksazolidin-5-karbonitril eller et akseptabelt salt derav.

- 5 **10.** Forbindelsen eller farmasøytisk akseptable salter derav, ifølge hvilket som helst av kravene 1–8, hvori forbindelsen representeres med følgende strukturell formel:



;

15 eller et farmasøytisk akseptabelt salt derav.

- 20 **11.** Farmasøytisk sammensetning omfattende en forbindelse ifølge hvilket som helst av kravene 1–10 og et farmasøytisk akseptabelt salt derav, og et farmasøytisk akseptabelt hjelpestoff eller fortynner.

- 12.** Forbindelse ifølge hvilket som helst av kravene 1–10 eller et farmasøytisk akseptabelt salt derav, til anvendelse ved behandling av en bakteriell infeksjon.

- 25 **13.** Forbindelse ifølge hvilket som helst av kravene 1–10 eller et farmasøytisk akseptabelt salt derav, til anvendelse for å hemme bakterielt DNA-gyrase.